Esparza José
Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA 98102, USA.
Vaccines (Basel). 2013 Oct 30;1(4):513-26. doi: 10.3390/vaccines1040513.
When HIV was discovered and established as the cause of AIDS in 1983-1984, many people believed that a vaccine would be rapidly developed. However, 30 years have passed and we are still struggling to develop an elusive vaccine. In trying to achieve that goal, different scientific paradigms have been explored. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. Major lessons learned are: the development of an HIV vaccine is an extremely difficult challenge; the temptation of just following the fashion should be avoided; clinical trials are critical, especially large-scale efficacy trials; HIV vaccine research will require long-term commitment; and sustainable collaborations are needed to accelerate the development of an HIV vaccine. Concrete actions must be implemented with the sense of urgency imposed by the severity of the AIDS epidemic.
1983年至1984年期间,当HIV被发现并确认为艾滋病病因时,许多人认为很快就能研发出疫苗。然而,30年过去了,我们仍在努力研发一种难以捉摸的疫苗。为实现这一目标,人们探索了不同的科学范式。尽管在理解HIV疫苗研发的科学基础方面取得了重大进展,但疗效试验对推动该领域发展至关重要。主要经验教训有:研发HIV疫苗是一项极其艰巨的挑战;应避免一味跟风的诱惑;临床试验至关重要,尤其是大规模疗效试验;HIV疫苗研究需要长期投入;需要可持续的合作来加速HIV疫苗的研发。必须以艾滋病疫情的严重性所带来的紧迫感来实施具体行动。